leadf
logo-loader
viewDe.mem

De.mem founding member of Singapore water treatment technology consortium

Government supported initiative aims to promote innovations in membranes.

Water
The consortium will connect research centres with small and medium enterprises

De.mem Ltd (ASX:DEM) is participating in a new Singapore Government initiative that aims to promote the use of innovations in water treatment.

The company is a founding member of Singapore National Membrane Consortium, which will promote the research, collaboration and commercialisation of membrane technologies.

This consortium will connect Singaporean research centres with small and medium enterprises such as De.mem that utilise membrane technology research to meet industry needs.

Capability to manufacture membranes

As one of the very few companies that can manufacture membranes in house, De.mem is one of 15 founding members of the consortium.

De.mem is a Singaporean-Australian decentralised water and waste-water treatment business with international operations.

Licensed proprietary technologies

The company has licensed a number of proprietary technologies from its research and development partner, Singapore’s Nanyang Technological University.

This includes a novel low-pressure hollow fibre nanofiltration membrane, which the company exclusively licensed from the university in June 2016.

The membrane allows for lower operating costs and capital expenditure compared to other conventional water treatment technologies.

Factory is established

De.mem has set up a factory for production of the membrane and other types of hollow fibre membranes.

Nanyang University’s Singapore Membrane Technology Centre is one of the research centres that will benefit from the consortium.

Another is the Membrane Science and Technology Consortium at the National University of Singapore.

Quick facts: De.mem

Price: 0.305 AUD

ASX:DEM
Market: ASX
Market Cap: $53.55 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Bionomics' positive pharmacokinetic results confirms it can begin second...

Bionomics Limited (ASX:BNO) (OTCQB:BNOEF) Executive Chairman Errol De Souza tells Proactive tells Proactive the Adelaide, Australia- based biopharmaceutical company has received positive pharmacokinetic results from a 7-day dosing study to treat PTSD, using its new formulation of BNC210. De...

2 days, 3 hours ago

2 min read